BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Vaklavas C, Forero-Torres A. Safety and efficacy of brentuximab vedotin in patients with Hodgkin lymphoma or systemic anaplastic large cell lymphoma. Ther Adv Hematol 2012;3:209-25. [PMID: 23606932 DOI: 10.1177/2040620712443076] [Cited by in Crossref: 53] [Cited by in F6Publishing: 44] [Article Influence: 6.6] [Reference Citation Analysis]
Number Citing Articles
1 Payan S, Montana M, Curti C, Greillier L, Vanelle P. Antibody-Drug Conjugates in Thoracic Malignancies: Clinical Trials Reveal Both Promise and Challenges. Target Oncol 2020;15:429-48. [PMID: 32725438 DOI: 10.1007/s11523-020-00740-y] [Reference Citation Analysis]
2 Bahou C, Richards DA, Maruani A, Love EA, Javaid F, Caddick S, Baker JR, Chudasama V. Highly homogeneous antibody modification through optimisation of the synthesis and conjugation of functionalised dibromopyridazinediones. Org Biomol Chem 2018;16:1359-66. [PMID: 29405223 DOI: 10.1039/c7ob03138f] [Cited by in Crossref: 36] [Cited by in F6Publishing: 13] [Article Influence: 18.0] [Reference Citation Analysis]
3 Zhou L, Xu N, Sun Y, Liu XM. Targeted biopharmaceuticals for cancer treatment. Cancer Lett 2014;352:145-51. [PMID: 25016064 DOI: 10.1016/j.canlet.2014.06.020] [Cited by in Crossref: 28] [Cited by in F6Publishing: 20] [Article Influence: 4.0] [Reference Citation Analysis]
4 Crisci S, Di Francia R, Mele S, Vitale P, Ronga G, De Filippi R, Berretta M, Rossi P, Pinto A. Overview of Targeted Drugs for Mature B-Cell Non-hodgkin Lymphomas. Front Oncol 2019;9:443. [PMID: 31214498 DOI: 10.3389/fonc.2019.00443] [Cited by in Crossref: 18] [Cited by in F6Publishing: 15] [Article Influence: 9.0] [Reference Citation Analysis]
5 Prokoph N, Larose H, Lim MS, Burke GAA, Turner SD. Treatment Options for Paediatric Anaplastic Large Cell Lymphoma (ALCL): Current Standard and beyond. Cancers (Basel). 2018;10. [PMID: 29601554 DOI: 10.3390/cancers10040099] [Cited by in Crossref: 34] [Cited by in F6Publishing: 27] [Article Influence: 11.3] [Reference Citation Analysis]
6 Chen T, Su D, Gruenhagen J, Gu C, Li Y, Yehl P, Chetwyn NP, Medley CD. Chemical de-conjugation for investigating the stability of small molecule drugs in antibody-drug conjugates. Journal of Pharmaceutical and Biomedical Analysis 2016;117:304-10. [DOI: 10.1016/j.jpba.2015.09.015] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 3.0] [Reference Citation Analysis]
7 Vaklavas C, Forero A. Management of metastatic breast cancer with second-generation antibody-drug conjugates: focus on glembatumumab vedotin (CDX-011, CR011-vcMMAE). BioDrugs 2014;28:253-63. [PMID: 24496926 DOI: 10.1007/s40259-014-0085-2] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 2.0] [Reference Citation Analysis]
8 Xu S. Internalization, Trafficking, Intracellular Processing and Actions of Antibody-Drug Conjugates. Pharm Res 2015;32:3577-83. [PMID: 26108878 DOI: 10.1007/s11095-015-1729-8] [Cited by in Crossref: 25] [Cited by in F6Publishing: 26] [Article Influence: 4.2] [Reference Citation Analysis]
9 Stack A, Levy I. Brentuximab vedotin as monotherapy for unresectable breast implant-associated anaplastic large cell lymphoma. Clin Case Rep 2019;7:1003-6. [PMID: 31110735 DOI: 10.1002/ccr3.2142] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
10 Wayua C, Roy J, Putt KS, Low PS. Selective Tumor Targeting of Desacetyl Vinblastine Hydrazide and Tubulysin B via Conjugation to a Cholecystokinin 2 Receptor (CCK2R) Ligand. Mol Pharm 2015;12:2477-83. [PMID: 26043355 DOI: 10.1021/acs.molpharmaceut.5b00218] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 3.0] [Reference Citation Analysis]
11 Dabir S, Kresak A, Yang M, Fu P, Wildey G, Dowlati A. CD30 is a potential therapeutic target in malignant mesothelioma. Mol Cancer Ther 2015;14:740-6. [PMID: 25589494 DOI: 10.1158/1535-7163.MCT-14-0972] [Cited by in Crossref: 16] [Cited by in F6Publishing: 6] [Article Influence: 2.7] [Reference Citation Analysis]
12 Chen R, Chen B. Brentuximab vedotin for relapsed or refractory Hodgkin's lymphoma. Drug Des Devel Ther 2015;9:1729-33. [PMID: 25848209 DOI: 10.2147/DDDT.S82007] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 1.5] [Reference Citation Analysis]
13 Gong J, Guo F, Cheng W, Fan H, Miao Q, Yang J. Preliminary biological evaluation of 123I-labelled anti-CD30-LDM in CD30-positive lymphomas murine models. Artif Cells Nanomed Biotechnol 2020;48:408-14. [PMID: 31913714 DOI: 10.1080/21691401.2019.1709857] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 5.0] [Reference Citation Analysis]
14 Parekh P, Kamble S, Zhao N, Zeng Z, Portier BP, Zu Y. Immunotherapy of CD30-expressing lymphoma using a highly stable ssDNA aptamer. Biomaterials 2013;34:8909-17. [PMID: 23968853 DOI: 10.1016/j.biomaterials.2013.07.099] [Cited by in Crossref: 50] [Cited by in F6Publishing: 51] [Article Influence: 6.3] [Reference Citation Analysis]
15 Kazemi T, Younesi V, Jadidi-Niaragh F, Yousefi M. Immunotherapeutic approaches for cancer therapy: An updated review. Artif Cells Nanomed Biotechnol 2016;44:769-79. [PMID: 25801036 DOI: 10.3109/21691401.2015.1019669] [Cited by in Crossref: 16] [Cited by in F6Publishing: 17] [Article Influence: 2.7] [Reference Citation Analysis]
16 Schirrmann T, Steinwand M, Wezler X, Ten Haaf A, Tur MK, Barth S. CD30 as a therapeutic target for lymphoma. BioDrugs 2014;28:181-209. [PMID: 24043362 DOI: 10.1007/s40259-013-0068-8] [Cited by in Crossref: 21] [Cited by in F6Publishing: 16] [Article Influence: 3.5] [Reference Citation Analysis]
17 Ottenhausen M, Bodhinayake I, Banu M, Kesavabhotla K, Ray A, Boockvar JA. Industry progress report on neuro-oncology: Biotech update 2013. J Neurooncol 2013;115:311-6. [DOI: 10.1007/s11060-013-1222-3] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
18 Peters C, Brown S. Antibody-drug conjugates as novel anti-cancer chemotherapeutics. Biosci Rep 2015;35:e00225. [PMID: 26182432 DOI: 10.1042/BSR20150089] [Cited by in Crossref: 204] [Cited by in F6Publishing: 71] [Article Influence: 34.0] [Reference Citation Analysis]
19 Pires ES, D'Souza RS, Needham MA, Herr AK, Jazaeri AA, Li H, Stoler MH, Anderson-Knapp KL, Thomas T, Mandal A, Gougeon A, Flickinger CJ, Bruns DE, Pollok BA, Herr JC. Membrane associated cancer-oocyte neoantigen SAS1B/ovastacin is a candidate immunotherapeutic target for uterine tumors. Oncotarget 2015;6:30194-211. [PMID: 26327203 DOI: 10.18632/oncotarget.4734] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.4] [Reference Citation Analysis]
20 Jackson D, Stover D. Using the Lessons Learned From the Clinic to Improve the Preclinical Development of Antibody Drug Conjugates. Pharm Res 2015;32:3458-69. [PMID: 25339341 DOI: 10.1007/s11095-014-1536-7] [Cited by in Crossref: 19] [Cited by in F6Publishing: 16] [Article Influence: 2.7] [Reference Citation Analysis]
21 Esnault C, Leblond V, Martin C, Desgranges A, Baltus CB, Aubrey N, Lakhrif Z, Lajoie L, Lantier L, Clémenceau B, Sarma B, Schrama J, Houben R, Schrama D, Hesbacher S, Gouilleux-Gruart V, Feng Y, Dimitrov D, Guyétant S, Berthon P, Viaud-Massuard MC, Samimi M, Touzé A, Kervarrec T. Adcitmer® , a new CD56-targeting monomethyl auristatin E-conjugated antibody, is a potential therapeutic approach in Merkel cell carcinoma. Br J Dermatol 2021. [PMID: 34582565 DOI: 10.1111/bjd.20770] [Reference Citation Analysis]
22 Khazir J, Riley DL, Pilcher LA, De-maayer P, Mir BA. Anticancer Agents from Diverse Natural Sources. Natural Product Communications 2014;9:1934578X1400901. [DOI: 10.1177/1934578x1400901130] [Cited by in Crossref: 12] [Article Influence: 1.7] [Reference Citation Analysis]
23 Donaghy H. Effects of antibody, drug and linker on the preclinical and clinical toxicities of antibody-drug conjugates. MAbs 2016;8:659-71. [PMID: 27045800 DOI: 10.1080/19420862.2016.1156829] [Cited by in Crossref: 189] [Cited by in F6Publishing: 156] [Article Influence: 37.8] [Reference Citation Analysis]
24 Dumaswala K, Mehta A. Novel agents for the treatment of Hodgkin lymphoma. Expert Rev Hematol 2015;8:659-67. [PMID: 26343891 DOI: 10.1586/17474086.2015.1081562] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
25 Bossard C, Dobay MP, Parrens M, Lamant L, Missiaglia E, Haioun C, Martin A, Fabiani B, Delarue R, Tournilhac O, Delorenzi M, Gaulard P, de Leval L. Immunohistochemistry as a valuable tool to assess CD30 expression in peripheral T-cell lymphomas: high correlation with mRNA levels. Blood 2014;124:2983-6. [PMID: 25224410 DOI: 10.1182/blood-2014-07-584953] [Cited by in Crossref: 57] [Cited by in F6Publishing: 53] [Article Influence: 8.1] [Reference Citation Analysis]
26 Alotaibi S, Hamadani M, Al-Mansour M, Aljurf M. Breast Implant-associated Anaplastic Large Cell Lymphoma. Clin Lymphoma Myeloma Leuk 2021;21:e272-6. [PMID: 33384263 DOI: 10.1016/j.clml.2020.12.005] [Reference Citation Analysis]
27 Coulson A, Levy A, Gossell-Williams M. Monoclonal Antibodies in Cancer Therapy: Mechanisms, Successes and Limitations. West Indian Med J 2014;63:650-4. [PMID: 25803383 DOI: 10.7727/wimj.2013.241] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 1.1] [Reference Citation Analysis]
28 Elgundi Z, Reslan M, Cruz E, Sifniotis V, Kayser V. The state-of-play and future of antibody therapeutics. Advanced Drug Delivery Reviews 2017;122:2-19. [DOI: 10.1016/j.addr.2016.11.004] [Cited by in Crossref: 136] [Cited by in F6Publishing: 115] [Article Influence: 34.0] [Reference Citation Analysis]
29 Rylova SN, Del Pozzo L, Klingeberg C, Tönnesmann R, Illert AL, Meyer PT, Maecke HR, Holland JP. Immuno-PET Imaging of CD30-Positive Lymphoma Using 89Zr-Desferrioxamine-Labeled CD30-Specific AC-10 Antibody. J Nucl Med 2016;57:96-102. [PMID: 26514172 DOI: 10.2967/jnumed.115.162735] [Cited by in Crossref: 24] [Cited by in F6Publishing: 17] [Article Influence: 4.0] [Reference Citation Analysis]
30 Onaindia A, Martínez N, Montes-moreno S, Almaraz C, Rodríguez-pinilla SM, Cereceda L, Revert JB, Ortega C, Tardio A, González L, García S, Camacho FI, González-vela C, Piris MA. CD30 Expression by B and T Cells: A Frequent Finding in Angioimmunoblastic T-Cell Lymphoma and Peripheral T-Cell Lymphoma-Not Otherwise Specified. American Journal of Surgical Pathology 2016;40:378-85. [DOI: 10.1097/pas.0000000000000571] [Cited by in Crossref: 20] [Cited by in F6Publishing: 10] [Article Influence: 4.0] [Reference Citation Analysis]
31 Mariotto S, Ferrari S, Sorio M, Benedetti F, Tridente G, Cavallaro T, Gajofatto A, Monaco S. Brentuximab vedotin: axonal microtubule's Apollyon. Blood Cancer J 2015;5:e343. [PMID: 26314985 DOI: 10.1038/bcj.2015.72] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 1.8] [Reference Citation Analysis]
32 Kaur N, Goyal A, Sindhu RK. Therapeutic Monoclonal Antibodies in Clinical Practice against Cancer. Anticancer Agents Med Chem 2020;20:1895-907. [PMID: 32619180 DOI: 10.2174/1871520620666200703191653] [Reference Citation Analysis]
33 Baeuerle P, Murry J. Human Therapies as a Successful Liaison between Chemistry and Biology. Chemistry & Biology 2014;21:1046-54. [DOI: 10.1016/j.chembiol.2014.08.014] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
34 Mehta A, Forero-torres A. Development and Integration of Antibody–Drug Conjugate in Non-Hodgkin Lymphoma. Curr Oncol Rep 2015;17. [DOI: 10.1007/s11912-015-0466-9] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 2.3] [Reference Citation Analysis]
35 Kim WY, Nam SJ, Kim S, Kim TM, Heo DS, Kim C, Jeon YK. Prognostic implications of CD30 expression in extranodal natural killer/T-cell lymphoma according to treatment modalities. Leukemia & Lymphoma 2015;56:1778-86. [DOI: 10.3109/10428194.2014.974048] [Cited by in Crossref: 27] [Cited by in F6Publishing: 28] [Article Influence: 3.9] [Reference Citation Analysis]
36 Ehrhardt MJ, Hochberg J, Bjornard KL, Brinkman TM. Long-term survivors of childhood, adolescent and young adult non-Hodgkin lymphoma. Br J Haematol 2019;185:1099-110. [PMID: 30714126 DOI: 10.1111/bjh.15775] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 3.5] [Reference Citation Analysis]
37 Saide A, Damiano S, Ciarcia R, Lauritano C. Promising Activities of Marine Natural Products against Hematopoietic Malignancies. Biomedicines 2021;9:645. [PMID: 34198841 DOI: 10.3390/biomedicines9060645] [Reference Citation Analysis]
38 Wang R, Li L, Zhang S, Li Y, Wang X, Miao Q, Zhen Y. A novel enediyne-integrated antibody-drug conjugate shows promising antitumor efficacy against CD30+ lymphomas. Mol Oncol 2018;12:339-55. [PMID: 29316337 DOI: 10.1002/1878-0261.12166] [Cited by in Crossref: 15] [Cited by in F6Publishing: 12] [Article Influence: 5.0] [Reference Citation Analysis]
39 Stack A, Ali N, Khan N. Breast Implant-associated Anaplastic Large Cell Lymphoma: A Review with Emphasis on the Role of Brentuximab Vedotin. J Cell Immunol 2020;2:80-9. [PMID: 32914146 DOI: 10.33696/immunology.2.025] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
40 Jordan SC, Choi J, Vo A. Achieving incompatible transplantation through desensitization: current perspectives and future directions. Immunotherapy 2015;7:377-98. [DOI: 10.2217/imt.15.10] [Cited by in Crossref: 18] [Cited by in F6Publishing: 14] [Article Influence: 3.0] [Reference Citation Analysis]
41 Romani C, Cocco E, Bignotti E, Moratto D, Bugatti A, Todeschini P, Bandiera E, Tassi R, Zanotti L, Pecorelli S, Sartori E, Odicino FE, de Marco A, Santin AD, Ravaggi A, Mitola S. Evaluation of a novel human IgG1 anti-claudin3 antibody that specifically recognizes its aberrantly localized antigen in ovarian cancer cells and that is suitable for selective drug delivery. Oncotarget 2015;6:34617-28. [PMID: 26416446 DOI: 10.18632/oncotarget.5315] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 1.8] [Reference Citation Analysis]
42 Jain S, Kumar S. Cancer immunotherapy: dawn of the death of cancer? Int Rev Immunol 2020;:1-18. [PMID: 32530336 DOI: 10.1080/08830185.2020.1775827] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
43 Pacheco JM, Camidge DR. Antibody drug conjugates in thoracic malignancies. Lung Cancer 2018;124:260-9. [PMID: 30268471 DOI: 10.1016/j.lungcan.2018.07.001] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
44 Lee WJ, Moon IJ, Shin HJ, Won CH, Chang SE, Choi JH, Lee MW. CD30-positive cutaneous extranodal natural killer/T-cell lymphoma: clinicopathological features and survival outcomes. Int J Dermatol 2019;58:688-96. [PMID: 30597548 DOI: 10.1111/ijd.14362] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]